Format

Send to

Choose Destination
Cancer Lett. 2007 Dec 8;258(1):9-21. Epub 2007 Oct 18.

Targeting the neural cell adhesion molecule in cancer.

Author information

1
Department of Paediatric Oncology and Haematology, University of Cologne, Kerpener Strasse 62, 50924, Cologne, Germany. jensen@uni-koeln.de

Abstract

NCAM is a tumour associated antigen expressed on small cell lung cancer, neuroblastoma, rhabdomyosarkoma, brain tumours, multiple myelomas and acute myeloid leukaemia. Constant and strong expression of NCAM is a prerequisite for the development of antibody-based immunotherapies. From the spectrum of existing anti-NCAM compounds, radioimmunoconjugates and immunotoxins represent the clinically most advanced and successful strategies. Here we provide an overview of the evolving field of anti-NCAM immunotherapy for cancer and discuss its indications and limitations.

PMID:
17949897
DOI:
10.1016/j.canlet.2007.09.004
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center